← All trials
NCT05734040
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2023
- Primary completion
- Aug 10, 2023
- Completion date
- Jan 10, 2024
- First posted
- Feb 17, 2023
- Last posted
- Sep 8, 2023
- Enrollment
- 478
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Osivax S.A.SLead sponsor
- NovotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.